Answer Summary

Members discussed treatment options beyond Jakavi (Jakafi) for myelofibrosis, with several sharing their own medication journeys including... Read more

Members discussed treatment options beyond Jakavi (Jakafi) for myelofibrosis, with several sharing their own medication journeys including switches to Ojjaaro, Inrebic/Fedratinib, and Momelotinib, while noting that multiple JAK inhibitors remain available if one stops working. Several members described common side effects like water retention and weight gain with Jakafi, the importance of monitoring spleen size before considering a transplant, and practical considerations such as taking B1/thiamine with certain medications to prevent serious complications. A recurring theme was the personalized nature of treatment progression, with members emphasizing that younger patients may be good transplant candidates, and that proactive spleen management and exploring donor matches early can help prepare for future treatment steps.